Learn more

About Proteorex

Our mission is to discover novel therapeutics for diseases with the highest unmet need, pushing the boundaries of drug discovery through innovative and world-class science.

Our award-winning small-molecule drug discovery platform uniquely integrates a novel synthesis design strategy, computational modelling, and patient-derived cell-based screening to rapidly and cost-effectively unlock targets considered undruggable using existing approaches.

Proteorex’s headquarters are in JLABS @ Toronto, with an office in San Francisco.

Hard-To-Drug Targets

Our technology has initially been applied to protein-protein interactions (PPIs) as they remain one of the highest potential, yet least explored targets in the treatment of human diseases. PPIs are the physical contacts of high specificity established between two or more protein molecules as a result of biochemical events. Many molecular processes within a cell are carried out by molecular machines that are built from a large number of associated protein components.

What We Do


Our team has developed an award-winning, next generation proprietary drug design and discovery technology, which is combined with high-powered computing and cutting-edge analytical tools to create a powerful drug discovery engine.


Proteorex Therapeutics is fully committed in advancing our R&D programs by building partnerships with pharmaceutical and biotechnology companies.


Proteorex is currently driving forward several programs in conjunction with partners. To inquire please Contact Us: info@proteorex.com

Stream our IndieBio Demo Day Presentation (9/14/2017 @ 3pm PST)

Join us on Thursday, September 14, 2017 at 3 PM PST, and watch our live Demo Day presentation, delivered by Dr. Marc Adler, Co-Founder and Director, Technology.


To watch the live stream, simply click on the play button below.


Our Team

Latest News